Creative Antibiotics

Ulf Boberg appointed CEO of Innate Pharmaceuticals

Pressmeddelande   •   Jul 06, 2009 08:00 CEST

Ulf Boberg, 56 years old, has more than 20 years of executive experience through assignments in biotechnology and pharmaceutical companies. Earlier Ulf Boberg has been appointed CEO in the Swedish biotechnology companies Affibody AB and Global Genetics AB and before that he has hold executive positions in Astra Pain Control and AstraZeneca.

Ulf Boberg has a proven understanding of managing clinical studies run by international pharmaceutical companies. He has also a broad commercial experience form early financing, deal making, and business development in biotechnology companies. Ulf Boberg is a trained pharmacist and earned his Doctors degree in medical sciences at Uppsala University and an MBA degree at the same University.

He will take up his duties as CEO of Innate Pharmaceutical - the name of the company being changed to Creative Antibiotics - in connection with the Annual Shareholders Meeting on October 28. Boberg succeeds Sune Rosell who has been appointed as CEO from the start of the Company in the year 2000. Ulf Boberg will be appointed Vice President as of September 1 and will work in parallel with Sune Rosell.

"I am very pleased that we have been able to recruit Ulf Boberg as a new CEO when the company is entering a new phase. His experience of clinical studies, collaboration with pharmaceutical enterprises and financing are crucial in order to continue a successful creation of shareholders value" says Ingemar Kihlström, chairman of the Board of Directors.

For further information, please contact Ingemar Kihlström, Chairman of the Board of Innate Pharmaceuticals AB, by telephone +46 733 821 102. E-mail: ingemar.kihlströ

Innate Pharmaceuticals AB (publ) was formed in 2000 to commercialise world-leading research at Umeå University and Karolinska Institutet in Stockholm. The company has developed and applied for patent protection for a number of chemical substances used to treat bacterial infections, known as virulence blocking antibiotics. These substances block the ability of certain bacteria to cause disease, without destroying them. If bacteria are disarmed in this way instead of being destroyed, the risk of bacteria developing resistance to drugs is reduced.